Pictet & Cie Europe SA acquired a new stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,705 shares of the biopharmaceutical company’s stock, valued at approximately $230,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC boosted its position in Alexion Pharmaceuticals by 25.1% during the 4th quarter. FMR LLC now owns 26,398,265 shares of the biopharmaceutical company’s stock worth $2,570,135,000 after purchasing an additional 5,301,272 shares during the period. Vanguard Group Inc boosted its position in Alexion Pharmaceuticals by 1.2% during the 3rd quarter. Vanguard Group Inc now owns 15,811,291 shares of the biopharmaceutical company’s stock worth $2,197,928,000 after purchasing an additional 192,857 shares during the period. Jennison Associates LLC boosted its position in Alexion Pharmaceuticals by 1.2% during the 4th quarter. Jennison Associates LLC now owns 8,728,912 shares of the biopharmaceutical company’s stock worth $849,847,000 after purchasing an additional 101,376 shares during the period. Norges Bank purchased a new stake in Alexion Pharmaceuticals during the 4th quarter worth $388,934,000. Finally, Northern Trust Corp boosted its position in Alexion Pharmaceuticals by 1.0% during the 4th quarter. Northern Trust Corp now owns 2,902,033 shares of the biopharmaceutical company’s stock worth $282,542,000 after purchasing an additional 30,016 shares during the period. 94.85% of the stock is owned by institutional investors.
A number of brokerages recently weighed in on ALXN. Royal Bank of Canada reaffirmed an “outperform” rating and set a $186.00 price target (up from $165.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, March 27th. TheStreet raised shares of Alexion Pharmaceuticals from a “c” rating to a “b” rating in a research report on Thursday, April 25th. BidaskClub cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 21st. Raymond James began coverage on shares of Alexion Pharmaceuticals in a research report on Wednesday, April 10th. They set an “outperform” rating and a $161.00 price target for the company. Finally, Morgan Stanley upped their price target on shares of Alexion Pharmaceuticals from $165.00 to $175.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 12th. Six research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $162.25.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.40. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. The firm’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.68 EPS. As a group, equities analysts expect that Alexion Pharmaceuticals, Inc. will post 8.6 earnings per share for the current year.
In other Alexion Pharmaceuticals news, CAO Daniel Bazarko sold 2,000 shares of the company’s stock in a transaction dated Thursday, February 14th. The shares were sold at an average price of $126.00, for a total value of $252,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,020 shares of the company’s stock, valued at approximately $632,520. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 4.08% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/05/04/1705-shares-in-alexion-pharmaceuticals-inc-alxn-acquired-by-pictet-cie-europe-sa.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Further Reading: Short Selling
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.